

# PHARMACOPEIAL FORUM

33

NUMBER 1

BIMONTHLY: January–February 2007

## Featured in This Issue

USP has identified the following content areas in the January–February 2007 issue of *Pharmacoepial Forum* as noteworthy for the pharmaceutical industry worldwide.

- Policies and Announcements
  - USP seeks Expert Committee member candidates for three Expert Committees
  - USP forms Stakeholder Forum to address the *Food Chemicals Codex*
  - In Memoriam – Dr. Joseph Robinson
  - USP Vice President of Pharmacopeial Education named
  - USP discontinues use of Intent to Comment Form
- Interim Revision Announcement Pertaining to *USP 29-NF 24*

A detailed listing of the Table of Contents of the January–February issue of *Pharmacoepial Forum* follows.



U.S. PHARMACOPEIA  
The Standard of Quality<sup>SM</sup>

---

---

# Table of Contents\*

PHARMACOPEIAL FORUM VOL. 33 NO. 1

JAN.–FEB. 2007

---

---

<b>STANDARDS DEVELOPMENT</b> .....	5
<b>HOW TO USE PF</b> .....	9
Section Descriptions .....	10
Committee Designations .....	12
Staff Directory .....	14
<b>POLICIES AND ANNOUNCEMENTS</b> .....	17
USP Seeks Candidates for Three Expert Committees .....	18
USP Forms Stakeholder Forum to Address the Food Chemicals Codex; First Meeting Set for February 2007 .....	18
Pharmacopeial Harmonization .....	18
In Memoriam: Joseph Robinson, Ph.D. ....	18
Vice President of Pharmacopeial Education Named .....	18
USP Discontinues Use of “Intent to Comment” Form .....	19
Implementation Period for Official Revisions to <i>USP–NF</i> Extended .....	19
Catalog to be Removed From <i>Pharmacopeial Forum</i> Print Publication .....	19
Stimuli Articles to be Posted on the USP’s Website .....	19
Pharmacopeial Education Courses .....	19
Visit the USP Website at <a href="http://www.usp.org">http://www.usp.org</a> .....	20
International Correspondence .....	20
How to Submit Comments .....	20
<i>Pharmacopeial Forum</i> Public Review and Comment Period Deadlines .....	21
Priority New Monograph Items .....	22
<b>INTERIM REVISION ANNOUNCEMENT</b> .....	31
<b>MONOGRAPHS (USP)</b> .....	35
Conjugated Estrogens Tablets .....	35
<b>ERRATA LIST FOR <i>USP–NF</i></b> .....	37
<b>IN-PROCESS REVISION</b> .....	39
<b>MONOGRAPHS (USP)</b> .....	41
Alprazolam Tablets (USP 31) .....	41
Bismuth Subsalicylate Oral Suspension (USP 31) .....	41
Bupropion Hydrochloride Extended-Release Tablets (Proposal for IRA) .....	42
Calcitriol (USP 31) .....	44
Citalopram Tablets (USP 31) .....	46
Cladribine (USP 31) .....	49
Clopidogrel Tablets (USP 31) .....	50
Cytarabine for Injection (USP 31) .....	51
Dimethyl Sulfoxide Gel (USP 31) .....	52
Enoxaparin Sodium [ <i>new</i> ] (USP 31) .....	52
Enoxaparin Sodium Injection [ <i>new</i> ] (USP 31) .....	58
Eprinomectin (USP 31) .....	60
Fluvastatin Sodium (USP 31) .....	64
Fosinopril Sodium and Hydrochlorothiazide Tablets (USP 31) .....	66
Hydrocortisone Tablets (USP 31) .....	72
Isosorbide Dinitrate Extended-Release Tablets (Proposal for IRA) .....	73
Levalbuterol Hydrochloride [ <i>new</i> ] (USP 31) .....	75
Levalbuterol Inhalation Solution [ <i>new</i> ] (USP 31) .....	79
Norethindrone Acetate and Ethinyl Estradiol Tablets (USP 31) .....	81
Pamidronate Disodium for Injection (Proposal for IRA) .....	81
Phenylbutazone Boluses (USP 31) .....	82
Phenylbutazone Tablets (USP 31) .....	82
Progesterone Vaginal Suppositories (USP 31) .....	82
Salicylic Acid (USP 31) .....	83

---

---

\* The *USP–NF* (*USP 31–NF 26*), the *Supplement (Supp)*, or the *Interim Revision Announcement (IRA)* for which the revision proposal is targeted is shown in parentheses next to each proposed item.

Valganciclovir Hydrochloride [ <i>new</i> ] (USP 31)	84
Valganciclovir Tablets [ <i>new</i> ] (USP 31)	89
DIETARY SUPPLEMENTS—MONOGRAPHS	93
Ubidecarenone Capsules (USP 31)	93
Ubidecarenone Tablets (USP 31)	94
GENERAL CHAPTERS	95
⟨11⟩ USP Reference Standards (USP 31)	95
GENERAL INFORMATION CHAPTERS	96
⟨1225⟩ Validation of Compendial Procedures (USP 31)	96
REAGENTS, INDICATORS, AND SOLUTIONS	100
<i>Reagent Specifications</i>	100
2-Aminoheptane [ <i>new</i> ] (USP 31)	100
Calconcarboxylic Acid [ <i>new</i> ] (USP 31)	100
Calconcarboxylic Acid Triturate [ <i>new</i> ] (USP 31)	100
Dimethicone, viscosity 500 centistokes [ <i>new</i> ] (USP 31)	100
Lactose (USP 31)	100
Propylamine Hydrochloride [ <i>new</i> ] (USP 31)	101
Sodium Phosphate Dibasic Dihydrate [ <i>new</i> ] (USP 31)	101
Triethylamine (USP 31)	101
<i>Volumetric Solutions</i>	101
Ceric Sulfate, Tenth-Normal (0.1 N) (USP 31)	102
Potassium Permanganate, Tenth-Normal (0.1 N) (USP 31)	103
<i>Chromatographic Reagents</i> [ <i>new</i> ] (USP 31)	104
REFERENCE TABLES	110
Description and Solubility (USP 31)	110
<b>PREVIOUS PF PROPOSALS STILL PENDING</b>	111
<b>CANCELED PROPOSALS</b>	137
<b>HARMONIZATION</b>	139
<b>PHARMACOPEIAL PREVIEWS</b>	141
<b>STIMULI TO THE REVISION PROCESS</b>	143
Instructions to Authors	145
<b>NOMENCLATURE</b>	147
<b>INDEX</b>	149

## STAFF DIRECTORY

This updated directory reflects assignment changes based on 2005–2010 Expert Committees. The general USP telephone number, (301) 881-0666, may still be used for general inquiries or when a particular Expert Committee is not identified. The fax number is (301) 816-8373.

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>Clydewyn M. Anthony, Ph.D.,</b> Scientist	cma@usp.org	(301) 816-8139	Monograph Development— Cough, Cold, and Analgesics (MD-CCA)
<b>Fouad Atouf, Ph.D.,</b> Senior Scientific Associate	fa@usp.org	(301) 816-8365	B&B Cell, Gene, and Tissue Therapies (BB CGT)
<b>Shawn C. Becker, M.S., B.S.N., R.N.,</b> Director, Patient Safety	scb@usp.org	(301) 816-8216	
<b>Daniel K. Bempong, Ph.D.,</b> Senior Scientist	dkb@usp.org	(301) 816-8143	Pulmonary and Steroids (MD-PS)
<b>Nancy Blum,</b> Vice President, International Affairs	nlb@usp.org	(301) 816-8161	
<b>William E. Brown,</b> Senior Scientist	web@usp.org	(301) 816-8380	Biopharmaceutics (BPC); Pharmaceutical Dosage Forms (PDF)
<b>Damián A. Cairatti,</b> Senior Scientist	dac@usp.org	(301) 816-8307	USP–NF Spanish Edition
<b>Larry N. Callahan, Ph.D.,</b> Senior Scientist	lnc@usp.org	(301) 816-8385	B&B Proteins and Polysaccha- rides (BB PP)
<b>Todd L. Cecil, Ph.D.,</b> Vice President, Standards Development	tlc@usp.org	(301) 816-8234	
<b>Diane Cousins, R.Ph.,</b> Vice President, Patient Safety	ddc@usp.org	(301) 816-8215	
<b>Behnam Davani, Ph.D.,</b> Senior Scientist	bd@usp.org	(301) 816-8394	Monograph Development— Antivirals and Antimicrobials (MD-AA)
<b>Ian F. DeVeau, Ph.D.,</b> Director, Veterinary Drugs and Radiopharmaceuticals	ifd@usp.org	(301) 816-8178	Veterinary Drugs (VET); Veterinary Medicine Information (VMI)
<b>Shawn F. Dressman, Ph.D.,</b> Director, Reference Standards Evaluation	sfd@usp.org	(301) 816-8261	Reference Standards (RS)
<b>Lawrence Evans, Ph.D.,</b> Scientist	le@usp.org	(301) 816-8389	Dietary Supplements—General Chapters (DS-GC); Dietary Supplements—Non- Botanicals (DSN)
<b>Gabriel I. Giancaspro, Ph.D.,</b> Director, Dietary Supplements	gig@usp.org	(301) 816-8343	
<b>Brian D. Gilbert, Ph.D.,</b> Scientist	bg@usp.org	(301) 816-8223	
<b>Elena Gonikberg, Ph.D.,</b> Senior Scientist	eg@usp.org	(301) 816-8251	Monograph Development— Gastrointestinal, Renal, and Endocrine (MD-GRE)
<b>Antonio Hernandez-Cardoso,</b> Scientist, Latin American Specialist	ahc@usp.org	(301) 816-8308	USP Spanish Edition; General Chapters (GC)
<b>Desmond G. Hunt, Ph.D.,</b> Senior Scientific Associate	dgh@usp.org	(301) 816-8341	Packaging and Storage (P&S); Parenteral Products— Industrial (PPI)

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>Robert Jacoby,</b> Manager, Editorial Services	raj@usp.org	(301) 998-6823	
<b>Ping Jin, Ph.D.,</b> Senior Scientific Associate	pj@usp.org	(301) 998-6827	Dietary Supplements— Bioavailability (DS-BA)
<b>James W. Kelly, Ph.D.,</b> Scientist	jwk@usp.org	(301) 816-8167	Compounding Pharmacy (CRX)
<b>Jymeann King, R.Ph.,</b> Drug Information Specialist	jk@usp.org	(301) 816-8507	Drug Information
<b>Robert Lafaver,</b> Scientist	rhl@usp.org	(301) 816-8335	Excipient Monographs 1 (EM1); Excipient General Chapters (EGC)
<b>Angela G. Long,</b> Vice President, Volunteer and Organizational Affairs and Executive Secretariat	agl@usp.org	(301) 816-8382	
<b>Victor Xiaobin Lu, Ph.D.,</b> Senior Scientist	vxl@usp.org	(301) 816-8336	B&B Vaccines and Virology (BB-VV)
<b>Anju K. Malhotra,</b> Manager, Scientific Administration	akm@usp.org	(301) 816-8346	
<b>Ronald G. Manning, Ph.D.,</b> Vice President, Monograph and Reference Standard Development	rgm@usp.org	(301) 816-8562	
<b>Feiwen Mao,</b> Senior Scientific Associate	fm@usp.org	(301) 816-8320	Monograph Development— Ophthalmology, Oncology, and Dermatology (MD-OOD)
<b>Margareth R. Marques, Ph.D.,</b> Senior Scientist and Latin American Liaison	mrm@usp.org	(301) 816-8106	Biopharmaceutics (BPC); Pharmaceutical Dosage Forms (PDF); Reagents
<b>Marcia D. Mayfield,</b> Manager, Monograph Development	mxm@usp.org	(301) 816-8358	
<b>Kate Meringolo,</b> Manager, Publication Support	kxm@usp.org	(301) 816-8377	
<b>Elizabeth Miller, Pharm.D.,</b> Manager	epc@usp.org	(301) 816-8217	Safe Medication Use (SMU)
<b>Kevin Moore, Ph.D.,</b> Scientist	ktm@usp.org	(301)816-8369	Harmonization; Monograph Improvement
<b>Tina S. Morris, Ph.D.,</b> Director, Biologics and Biotechnology	tsm@usp.org	(301) 816-8397	
<b>Amy Neal, DVM,</b> Senior Scientist	an@usp.org	(301) 998-6786	Veterinary Medicine Information (VMI)
<b>Claudia C. Okeke, Ph.D.,</b> Scientific Fellow, Patient Safety	cco@usp.org	(301) 816-8243	Sterile Compounding (SCC)
<b>Horacio Pappa, Ph.D.,</b> Senior Scientist and Latin American Liaison	hp@usp.org	(301) 816-8319	General Chapters (GC); Statistics (STAT)
<b>W. Larry Paul, Ph.D.,</b> Scientific Fellow	wlp@usp.org	(301) 816-8331	Nomenclature (NOM)
<b>Denise Penn, R.Ph.,</b> Drug Information Specialist	dsp@usp.org	(301) 816-8392	Drug Information
<b>Deborah G. Perfetto, Pharm.D.,</b> Director, Information Programs	dgp@usp.org	(301) 816-8317	
<b>Sujatha Ramakrishna, Ph.D.,</b> Scientist	syk@usp.org	(301) 816-8349	Monograph Development— Cardiovascular (MD-CV)

STAFF	E-MAIL	PHONE	ASSIGNMENT
<b>Ravi Ravichandran, Ph.D.,</b> Senior Scientist	rr@usp.org	(301) 816-8330	Monograph Development— Psychiatrics and Psychoactives (MD-PP)
<b>Gary E. Ritchie, M.S.,</b> Scientific Fellow for PAT	ger@usp.org	(301) 816-8353	General Chapters (GC); Pharmaceutical Waters (PW); Statistics (STAT)
<b>Karen A. Russo, Ph.D.,</b> Director, Small Molecules and Monograph Acquisition	kar@usp.org	(301) 816-8379	Monograph Acquisition and Infrastructure
<b>Leonel Santos,</b> Senior Scientist	lxs@usp.org	(301) 816-8168	International Health (IH)
<b>Dandapantula Sarma, Ph.D.,</b> Senior Scientist	dns@usp.org	(301) 816-8354	Dietary Supplements— Information (DSI)
<b>Stefan P. Schuber, Ph.D.,</b> Director, Scientific Reports	sps@usp.org	(301) 816-8551	
<b>Maged H. M. Sharaf, Ph.D.,</b> Senior Scientist	mhs@usp.org	(301) 816-8318	Dietary Supplements— Botanicals (DSB); Dietary Supplements— General Chapters (DS-GC)
<b>Catherine M. Sheehan,</b> Director, Excipients	cxs@usp.org	(301) 816-8262	
<b>Anita Y. Szajek, Ph.D.,</b> Senior Scientist	aey@usp.org	(301) 816-8325	B&B Blood and Blood Products (BB BBP)
<b>Radhakrishna S. Tirumalai, Ph.D.,</b> Senior Scientist	rst@usp.org	(301) 816-8339	General Toxicity and Medical Device Biocompatibility (GTMDB); Microbiology and Sterility Assurance (MSA)
<b>Beryl Voigt,</b> Director, Executive Secretariat	bev@usp.org	(301) 816-8155	
<b>Hong Wang, Ph.D.,</b> Senior Scientific Associate	hw@usp.org	(301) 816-8351	Excipient Monographs 2 (EM2); Excipient General Chapters (EGC)
<b>Andrzej Wilk, Ph.D.,</b> Scientist	aw@usp.org	(301) 816-8305	Radiopharmaceuticals and Medical Imaging Agents (RMI); Radiopharmaceutical Information (RI)
<b>Kahkashan Zaidi, Ph.D.,</b> Senior Scientist	kxz@usp.org	(301) 816-8269	Aerosols (AER); General Chapters (GC)

**USP SEEKS CANDIDATES FOR THREE EXPERT COMMITTEES.** In accordance with Chapter 10 of the Bylaws of the USP Convention, USP is seeking qualified candidates for its Expert Committees. Specifically, USP is seeking candidates to fill vacancies on the following 2005–2010 Expert Committees:

- Information: Clinical Toxicology
- Information: Nephrology and Urology

In addition, as a result of USP's acquisition of the *Food Chemicals Codex (FCC)*, the Board of Trustees and the Executive Committee of the Council of Experts have approved the formation of a new Expert Committee. Candidates are also being sought for this Committee:

- Standards: Food Additives

Expert Committee members directly influence drug quality in the United States and many other countries by establishing quality standards and information in the *United States Pharmacopeia* and the *National Formulary*, the *Food Chemicals Codex*, and the Medicare Model Guidelines. Expert Committee members also help further the best practices in pharmaceutical science nationally and globally.

**The Nominations Process.** Anyone can apply to be a potential candidate for Expert Committees via the candidate application on the USP website ([www.usp.org/nominate](http://www.usp.org/nominate)). Applicants will be asked to identify the Expert Committee(s) position for which they wish to be considered, and indicate their professional experience, education, USP experience, and other relevant experience.

Nominations for Expert Committee member positions close on **February 15, 2007**. Expert Committee member elections will be held in the **Spring 2007**. For further information, contact the Department of Volunteer and Organizational Affairs at [nominate@usp.org](mailto:nominate@usp.org).

**USP FORMS STAKEHOLDER FORUM TO ADDRESS THE FOOD CHEMICALS CODEX; FIRST MEETING SET FOR FEBRUARY 2007.** In addition to the newly formed Food Additives Expert Committee, for which USP is seeking chairs and members (see above article) and an associated ad hoc Advisory Panel, USP has also formed a *Food Chemicals Codex* Stakeholder Forum. Invited FCC stakeholder organizations participated in an organizing teleconference for the Stakeholder Forum at the end of November, and the first FCC Stakeholder Forum meeting is set for February 23, 2007, at the Marriott Bethesda North Hotel (see USP's website for further information: <http://www.usp.org/eventsEducation/calendar.html>).

The charge of the *Food Chemicals Codex* Stakeholder Forum is to provide information and advice to USP's CEO-EVP, staff, and Council of Experts standards-setting bodies for the *Food Chemicals Codex*.

Depending on deliberations in the Stakeholder Forum, Project Teams on special topics of interest may be formed to generate specific data and information in support of the Council of Experts' standards-setting activities for *Food Chemicals Codex*. Communications to and from other USP Stakeholder Forums is expected to be valuable as USP charts its course for the FCC.

Contact Ms. Helen Kharab ([hk@usp.org](mailto:hk@usp.org) or 301-816-8224) for further information.

**PHARMACOPEIAL HARMONIZATION.** The Pharmacopeial Discussion Group (PDG) held its meeting October 23–26, 2006, in Chicago, IL. A press release outlining its work from this and previous meetings is available on USP's website at <http://www.usp.org/USPNF/pharmacopeialHarmonization/>.

#### **IN MEMORIAM: JOSEPH ROBINSON, PH.D.**

USP is saddened to announce that Dr. Joseph Robinson (1939–2006) passed away in September 2006. He was a member of USP's Council of Experts/Committee of Revision from 1980 to 2000. During that time, he served as the chair and as a member of the Expert Committee on Bioavailability, Bioequivalence, and Dissolution. Dr. Robinson was Professor of Pharmacy in the School of Pharmacy and Professor of Ophthalmology in the Medical School at the University of Wisconsin–Madison. He earned his B.S. and M.S. degrees from Columbia University in New York and his Ph.D. from the University of Wisconsin. He was a major contributor to the field of pharmaceutical science.

**VICE PRESIDENT OF PHARMACOPEIAL EDUCATION NAMED.** Toby Gouker joined USP as Vice President, Pharmacopeial Education, in September 2006. Toby has over 25 years of diverse business, technical, and training experience and a demonstrated track record of success as an education and training executive. Toby comes to USP from the American Graduate University (AGU). At AGU, Toby was Vice President, University Affairs, functioning as chief academic and operations officer responsible for program conception and development and delivery of courses and programs throughout the US and in more than 25 other countries. He was also responsible for faculty recruiting and drafting the annual business, budget, and marketing plans. Prior to joining AGU, Toby was Executive Director, Walden National Technology University, School of Engineering with Laureate Education. Previous positions included Director, Operations, for Certis USA, and Research & Development Project Manager at W. R. Grace & Co. Toby received a B.S. in Chemical Engineering from Worcester Polytechnic Institute, Worcester, MA, and an M.B.A. from the University of Houston, Clerk Lake City, TX. Toby is currently pursuing a Ph.D. in Information Systems Management with concentration in Online Training from Walden University.

**USP DISCONTINUES USE OF “INTENT TO COMMENT” FORM.** Beginning with this issue of *Pharmacopeial Forum*, the “Intent to Comment” form has been removed from the back of the publication. Previously, the comment period for each issue of PF was 60 days. In 2005, the comment period was increased to 90 days. With this expansion in the comment period, it was no longer viewed as necessary or appropriate to routinely allow further extensions of time to comment through the “Intent to Comment” form. In order to ensure that comments on a proposed revision will be considered by the Expert Committee in determining whether and how a proposed revision should proceed, comments should be received within the 90-day comment period.

Please direct any comments or questions on this topic to Beryl Voigt, Director, Executive Secretariat (301-816-8155 or [execsec@usp.org](mailto:execsec@usp.org)).

**IMPLEMENTATION PERIOD FOR OFFICIAL REVISIONS TO USP–NF EXTENDED.** To provide additional time to adopt revisions made to the compendia, effective beginning with the publication of *USP 30–NF 25*, implementation periods for revisions to official text in the *United States Pharmacopeia–National Formulary (USP–NF)* and its *Supplements* are being extended. This change is in response to stakeholder requests (see the *Pharmacopeial Forum [PF]* 31[2] *Stimuli* article, “The USP Revision Process: Recommendations for Enhancements”). As a result of this change, users have six months from the publication date to implement new official texts, as opposed to the previous 60-day period. The complete revised Publication Schedule for *USP 30–NF 25*, reflecting this new six-month implementation period, is outlined below.

**Publication Schedule for USP 30–NF 25**

<b>USP–NF Publication</b>	<b>Publication Date</b>	<b>Official Date</b>
<i>USP–NF</i> (Book)	November 2006	May 1, 2007
Supplement One	February 2007	August 1, 2007
Supplement Two	June 2007	December 1, 2007

Users may implement the newly official texts prior to the official date, and the use becomes mandatory on the official date.

Please direct any comments or questions on this topic to Beryl Voigt, Director, Executive Secretariat (301-816-8155 or [execsec@usp.org](mailto:execsec@usp.org)).

**CATALOG TO BE REMOVED FROM PHARMACOPEIAL FORUM PRINT PUBLICATION.** Beginning with this issue of *Pharmacopeial Forum*, the USP Catalog is no longer being included in the back of the publication. This change has been made to reduce the bulk of the publication and thereby increase ease of handling and use.

The USP Catalog is still available in online and stand-alone print versions. Online bimonthly and daily catalogs can be accessed at [www.usp.org/referenceStandards/catalog.html](http://www.usp.org/referenceStandards/catalog.html). You can also sign up to receive the USP Catalog in print (via postal mail) along with monthly email alerts—which will keep you informed about new Reference Standards, availability, and current lots—by sending an e-mail to [marketing@usp.org](mailto:marketing@usp.org) or calling 301-816-8237.

**STIMULI ARTICLES TO BE POSTED ON THE USP WEBSITE.** Starting in 2007, the *Stimuli* articles that are published in *Pharmacopeial Forum* will be simultaneously published on the USP website. Look for them at [www.usp.org](http://www.usp.org). There are no *Stimuli* articles in this issue of *Pharmacopeial Forum*, but those that will be published in the next issue of *Pharmacopeial Forum* will appear on the website in March 2007. For more information, please contact Stefan Schuber, Ph.D., Director, Scientific Reports (301-816-8551 or [sps@usp.org](mailto:sps@usp.org)).

**PHARMACOPEIAL EDUCATION COURSES.** The USP Pharmacopeial Education courses offer specialized instruction for chemists, other scientists, and professionals in the pharmaceutical and allied industries. USP scientists and USP science experts, who play a key role in establishing official USP standards, teach these courses and provide expert insights into the practical applications of official test procedures and best practices in using the *USP–NF* and other USP resources. The courses also give participants an opportunity to learn how to get involved in USP’s standards-setting processes and the benefits of participating in standards development. Courses offered in 2007 are listed below. For more information and to register, visit [www.usp.org/goto/pe](http://www.usp.org/goto/pe). To discuss how USP can bring courses to a location of your choice, call 301-816-8589, or e-mail [PharmacopeialEducation@usp.org](mailto:PharmacopeialEducation@usp.org).

Beginning in the 2007 calendar year, USP’s Pharmacopeial Education (PE) program will be initiating a significant expansion initiative. Both the depth and breadth of course offerings will grow as the Pharmacopeial Education staff works to make the science behind the standards more accessible. As this process begins, the PE program invites you to participate by suggesting titles, developing course objectives, or even joining the teaching staff.

## Calendar of Forthcoming Pharmacopeial Education Courses as of November 15, 2006

Date	Name of Course	Location	Price
<b>The Americas</b>			
30-31 Jan-07	Effectively Using the USP–NF—Sessions I & II	Rockville, MD (USP Headquarters, 2 days)	\$1,700
8-Feb-07	Navigating Chapter <467> Residual Solvents (new)	Rockville, MD (USP Headquarters, 1/2 day)	\$245
13-Feb-07	Navigating Chapter <467> Residual Solvents (new)	Raleigh, NC (1/2-day seminar)	\$245*
23-Feb-07	Essentials of USP Microbiological Testing (new course)	Irvine, CA	\$595
27-Feb-07	Navigating Chapter <467> Residual Solvents (new)	Chicago, IL (during Pittcon)	\$245*
Winter 2007	Navigating Chapter <467> Residual Solvents (new)	Dallas/Fort Worth, TX (details to come)	\$245*
15-Mar-07	Essentials of USP Microbiological Testing (new course)	Raleigh, NC	\$595
15-Mar-07	Analytical Method Validation (in Spanish)	Mexico City, Mexico (details to come)	TBD
Mar-07	Navigating Chapter (467) Residual Solvents (new)	Montreal, Canada (details to come)	TBD
Mar-07	Navigating Chapter (467) Residual Solvents (new)	East Brunswick, NJ (details to come)	\$245*
May 07	Navigating Chapter (467) Residual Solvents (new)	Rockville, MD (USP Headquarters, 1/2 day)	\$245

\* Two identical half-day seminars, morning and afternoon, will be offered. To register, send your contact information by e-mail to [PharmacopeialEducation@usp.org](mailto:PharmacopeialEducation@usp.org) to receive a flier/registration form by return e-mail. If space permits, registrations accepted less than one week before the course will be \$295.

**VISIT THE USP WEBSITE AT <http://www.usp.org>.** Various resources related to Pharmacopeial standards are presented, including highlights from *PF*.

**INTERNATIONAL CORRESPONDENCE.** Individuals who wish to correspond with the European and Japanese Pharmacopoeias concerning monographs in the Official Inquiry and Consensus stages of international harmonization should address their comments to the coordinating pharmacopeia, with a copy to USP, for a given article. The addresses for the European and Japanese Pharmacopoeias are as follows:

Technical Secretariat of the European  
Pharmacopoeia Commission  
B.P. 907  
F 67029 Strasbourg Cedex 1  
France

NAKASHIMA Nobumasa  
Evaluation and Licensing Division  
Pharmaceutical and Medical Safety Bureau  
Ministry of Health, Labour and Welfare, Japan  
Tel. +81-3-3595-2431, Fax +81-3-3597-9535  
E-mail: [nakashima-nobumasa@mhlw.go.jp](mailto:nakashima-nobumasa@mhlw.go.jp)

**HOW TO SUBMIT COMMENTS.** The USP welcomes and encourages interested parties to submit comments and data regarding potential, proposed, or adopted (official) standards. Submissions concerning a particular item that has appeared in an issue of *PF* should be submitted to the appropriate USP scientific staff liaison identified at the end of the *Briefing* accompanying each item. To submit comments and data to a liaison, use the e-mail address and telephone numbers listed in the *Staff Directory* included in every *PF*.

Please note that *USP–NF* is being published in an annual edition with one main book and two *Supplements* a year. In addition, the schedule provided below will repeat every year so that users will know what to expect and will become familiar with the deadlines.

For general inquiries or in cases where a particular liaison is not identified, use the general USP telephone number 301-881-0666 or fax number 301-816-8373.

**PHARMACOPEIAL FORUM PUBLIC REVIEW AND COMMENT PERIOD DEADLINES.** The full year’s listing of comment period deadlines and targeted official publications appears below. In accordance with the Rules and Procedures of the 2005–2010 Council of Experts, USP has implemented a 90-day comment period by providing a deadline for each issue of *PF* unless otherwise stated in the

individual *Briefing*. As previously stated, as a result of the comment deadline extension, the “Intent to Comment” form will no longer be used and will be removed from *PF*. The listing of comment period deadlines and the targeted official publications appear below.

Pharmacopeial Forum	Comment Deadline	Targeted Official Publication	Publication Date	Official Date
<i>PF</i> 32(6)	February 15, 2007	<i>USP 31–NF 26</i>	November 2007	May 2008
<i>PF</i> 33(1)	April 16, 2007			
<i>PF</i> 33(2)	June 15, 2007	<i>USP 31–NF 26</i> <i>1st Supplement</i>	February 2008	August 2008
<i>PF</i> 33(3)	August 15, 2007			
<i>PF</i> 33(4)	October 15, 2007	<i>USP 31–NF 26</i> <i>2nd Supplement</i>	June 2008	December 2008
<i>PF</i> 33(5)	December 15, 2007			
<i>PF</i> 33(6)	February 15, 2008	<i>USP 32–NF 27</i>	November 2008	May 2009
<i>PF</i> 34(1)	April 15, 2008			

All official revisions are published in the annual edition or *Supplements* to *USP–NF* (twice yearly). Between these publications, official revisions are published in *PF* in the *Interim Revision Announcement*; these revisions are also incorporated in the upcoming *Supplement*. The official publication in which an *IRA* is incorporated will depend upon publication deadlines. The *IRAs* appearing in *PF* Numbers 5 and 6 of each volume will not appear until *Supplement 1*. See table below. The

electronic version of *USP–NF* is updated as each *Supplement* becomes available and, therefore, contains all official text up to and including the contents of the latest *Supplement*. The new table below outlines the publications and their release and official dates, and the book or supplement that supersedes them.

**Publication Schedules**

Publication	Release Date	Official Date	Superseded by
4th <i>IRA</i> [ <i>PF</i> 32(4)]	July 1, 2006	Aug. 1, 2006	<i>USP 30–NF 25</i>
5th <i>IRA</i> [ <i>PF</i> 32(5)]	Sept. 1, 2006	Oct. 1, 2006	<i>1st Supplement</i>
6th <i>IRA</i> [ <i>PF</i> 32(6)]	Nov. 1, 2006	Dec. 1, 2006	<i>1st Supplement</i>
<i>USP 30–NF 25</i>	Nov. 1, 2006*	May 1, 2007*	<i>1st Supplement</i>
<i>IRA</i> [ <i>PF</i> 33(1)]	Jan. 1, 2007*	Feb. 1, 2007*	<i>2nd Supplement</i>
<i>1st Supplement</i>	Feb. 1, 2007*	Aug. 1, 2007*	<i>2nd Supplement</i>
<i>IRA</i> [ <i>PF</i> 33(2)]	Mar. 1, 2007*	Apr. 1, 2007*	<i>2nd Supplement</i>
<i>IRA</i> [ <i>PF</i> 33(3)]	May 1, 2007*	June 1, 2007*	<i>USP 31–NF 26</i>
<i>2nd Supplement</i>	June 1, 2007*	Dec. 1, 2007*	<i>USP 31–NF 26</i>
<i>IRA</i> [ <i>PF</i> 33(4)]	July 1, 2007*	Aug. 1, 2007*	<i>USP 31–NF 26</i>
<i>IRA</i> [ <i>PF</i> 33(5)]	Sept. 1, 2007*	Oct. 1, 2007*	<i>1st Supplement to</i> <i>USP 31–NF 26</i>
<i>IRA</i> [ <i>PF</i> 33(6)]	Nov. 1, 2007*	Dec. 1, 2007*	<i>1st Supplement to</i> <i>USP 31–NF 26</i>
<i>USP 31–NF 26</i>	Nov. 1, 2007*	May 1, 2008*	<i>1st Supplement to</i> <i>USP 31–NF 26</i>

\* Tentative.

**PRIORITY NEW MONOGRAPH ITEMS.** USP is seeking monographs for the following drug substances and drug products that are or soon will be off patent and thus are of the highest priority. USP also is seeking monographs for the excipients listed below. Monographs are marked received upon receipt of the monograph proposal. Received monographs are removed from this list upon publication in *Pharmacopeial*

*Forum*. (This list has been updated as of September 1, 2006.) For additional information, contact Karen A. Russo, Ph.D., kar@usp.org. Monograph sponsors should consult USP's *Guideline for Submitting Requests for Revision to the USP–NF*.

**Noncomplex Actives (Drug Substances)**

Acarbose <i>(Received)</i>	Alatrofloxacin Mesylate	Alfuzosin Hydrochloride <i>(Received)</i>
Allopurinol Sodium	Aminopromazine Fumarate	Aminopterin Sodium
Anagrelide Hydrochloride	Arsenic Trioxide	Auranfoin
Azelaic Acid	Balsalazide Disodium	Bentoquatam
Benzphetamine Hydrochloride	Bepidil Hydrochloride	Bivalirudin
Cabergoline <i>(Received)</i>	Calcipotriene	Calcium Trisodium Pentetate
Calfactant	Candesartan Cilexetil	Carmustine <i>(Received)</i>
Cefdinir <i>(Received)</i>	Cefditoren Pivoxil	Ceftibuten
Ceftiofur Hydrochloride	Cysteamine Bitartrate	Cetrorelix
Cevimeline	Chloroxine	Choline Salicylate
Colfosceril	Cytarabine Liposome	Dalfopristin
Dapirazole Hydrochloride	Desirudin	Desonide <i>(Received)</i>
Dexrazoxane	Dextromethorphan Polistirex	Difenoxin Hydrochloride
Difloxacin Hydrochloride	Diltiazem Malate	Doxacurium Chloride
Entacapone	Epoprostenol Sodium <i>(Received)</i>	Erythromycin Phosphate
Erythromycin Thiocyanate	Esmolol Hydrochloride	Esomeprazole Magnesium <i>(Received)</i>
Estazolam	Estradiol Benzoate <i>(Received)</i>	Estramustine Phosphate Sodium
Ethanolamine Oleate	Etomidate <i>(Received)</i>	Etoposide
Exemestane	Felbamate	Flavoxate Hydrochloride
Fluoromethane F 18	Foscarnet Sodium <i>(Received)</i>	Fosfomycin Tromethamine <i>(Received)</i>
Gadobenate Dimeglumine	Gadopentetic Acid	Galantamine Hydrobromide <i>(Received)</i>
Gallium Nitrate	Ganirelix	Glyceryl Aminobenzoate
Granisetron Hydrochloride <i>(Received)</i>	Guanidine Hydrochloride	Halobetasol Propionate <i>(Received)</i>
Haloperidol Decanoate <i>(Received)</i>	Hydrocodone Polistirex	Ibandronate Sodium
Imipramine Pamoate	Imiquimod	Irinotecan
Isosulfan Blue	Itraconazole <i>(Received)</i>	Lamotrigine <i>(Received)</i>
Latanoprost	Levetiracetam	Levobetaxolol
Levomethadyl Acetate	Lomustine <i>(Received)</i>	Lopinavir
Metipranolol Hydrochloride	Midazolam <i>(Received)</i>	Mifepristone <i>(Received)</i>
Miglitol	Milrinone Lactate	Misoprostol <i>(Received)</i>
Mivacurium Chloride	Moexipril Hydrochloride	Nalbuphine Hydrochloride
Nalmefene Hydrochloride	Nateglinide <i>(Received)</i>	Nedocromil Sodium
Nicardipine Hydrochloride	Nilutamide	Nisoldipine
Olopatadine <i>(Received)</i>	Olsalazine Sodium <i>(Received)</i>	Orbifloxacin <i>(Received)</i>
Orlistat <i>(Received)</i>	Oxcarbazepine <i>(Received)</i>	Oxiconazole Nitrate

Noncomplex Actives (Drug Substances) (Continued)

Pantoprazole Sodium <i>(Received)</i>	Pemirolast Potassium	Pemoline
Pentamidine Isethionate <i>(Received)</i>	Piperonyl Butoxide	Pirbuterol Acetate
Poractant Alpha	Porfimer Sodium	Pramiprexole Dihydrochloride
Proguanil Hydrochloride <i>(Received)</i>	Quetiapine Fumarate <i>(Received)</i>	Ranitidine
Rivastigmine Tartrate	Rose Bengal	Rosiglitazone Maleate
Salmeterol Xinafoate	Sertraline Hydrochloride <i>(Received)</i>	Sodium Phenylbutyrate
Sodium Phosphates	Spectinomycin Sulfate	Streptozocin
Sulfacytine	Tacrolimus	Tenofovir Disoproxil Fumarate
Terbinafine Hydrochloride <i>(Received)</i>	Terconazole <i>(Received)</i>	Tiludronate Disodium
Tiopronin	Trandolapril	Tranexamic Acid <i>(Received)</i>
Tranlycypromine Sulfate	Trimetrexate Glucuronate	Trimipramine Maleate <i>(Received)</i>
Trovafloxacin Mesylate	Unoprostone Isopropyl	Venlafaxine Hydrochloride
Voriconazole	Zinc Tridosium Pentetate	Zoledronic Acid

Noncomplex Actives (Drug Products)

Abacavir Sulfate, Lamivudine, and Zidovudine Tablets	Acarbose Tablets	Acetaminophen, Butalbital, Caffeine, and Codeine Phosphate Capsules
Acetaminophen, Clemastine Fumarate, and Pseudoephedrine Hydrochloride Tablets	Acetazolamide Extended-Release Capsules	Albuterol Extended-Release Tablets
Albuterol for Inhalation	Albuterol Inhalation Aerosol	Alendronate Sodium Oral Solution
Alfuzosin Tablets	Allopurinol for Injection	Alprazolam Extended-Release Tablets
Alprostadil Urethral Suppository	Aminopromazine Fumarate and Neomycin Sulfate Tablets	Aminopromazine Fumarate Injection
Aminopromazine Fumarate Tablets	Aminopterin Sodium Tablets	Amlodipine and Benazepril Hydrochloride Capsules
Amphotericin B Injection	Anagrelide Hydrochloride Capsules	Arsenic Trioxide Injection
Atovaquone and Proguanil Hydrochloride Tablets	Atovaquone Tablets	Auranofin Capsules
Azatadine Maleate and Pseudoephedrine Sulfate Extended-Release Tablets	Azelaic Acid Cream	Azithromycin for Injection <i>(Received)</i>
Azithromycin Tablets	Baclofen Injection	Balsalazide Disodium Capsules
Beclomethasone Dipropionate Inhalation Aerosol	Beclomethasone Dipropionate Nasal Suspension	Bentoquatam Topical Suspension
Benzocaine and Cetylpyridinium Chloride Lozenges	Benzocaine and Menthol Lotion	Benzphetamine Hydrochloride Tablets
Bepidil Tablets	Bicalutamide Tablets	Bivalirudin Injection
Brompheniramine Maleate, Dextromethorphan Hydrobromide, and Pseudoephedrine Hydrochloride Oral Solution	Budesonide Inhalation Aerosol	Bupivacaine and Lidocaine Hydrochlorides Injection
Buprenorphine Hydrochloride Injection	Butalbital and Acetaminophen Capsules	Butalbital and Acetaminophen Tablets
Calcipotriene Cream	Calcipotriene Ointment	Calcipotriene Topical Solution
Cabergoline Tablets	Calcitriol Capsules	Calcitriol Oral Solution
Calcium Acetate Capsules	Calcium Trisodium Pentetate Injection	Calfactant Intratracheal Suspension
Carbidopa and Levodopa Extended-Release Tablets <i>(Received)</i>	Carbidopa and Levodopa Tablets for Oral Suspension <i>(Received)</i>	Carbidopa, Levodopa, and Entacapone Tablets
Carmustine for Injection <i>(Received)</i>	Carmustine Implant	Carvedilol Tablets <i>(Received)</i>
Cefdinir Tablets	Cefditoren Pivoxil Tablets	Ceftibuten Capsules
Ceftibuten for Oral Suspension	Ceftiofur Hydrochloride Oral Suspension	Cetirizine Hydrochloride Oral Solution
Cetirizine Hydrochloride Tablets <i>(Received)</i>	Cetrorelix Injection	Cevimeline Hydrochloride Capsules
Chloroxine Cream	Chlorpromazine Hydrochloride Extended-Release Capsules	Choline and Magnesium Salicylates Oral Solution

## Noncomplex Actives (Drug Products) (Continued)

Choline and Magnesium Salicylates Tablets	Choline Salicylate Oral Solution <b>(Received)</b>	Ciclopirox Shampoo
Ciclopirox Topical Gel	Ciclopirox Topical Solution	Cilostazol Tablets <b>(Received)</b>
Cimetidine Oral Solution	Ciprofloxacin Hydrochloride and Hydrocortisone Otic Suspension	Ciprofloxacin Otic Solution
Citalopram Hydrobromide Oral Solution	Citric Acid, Gluconolactone, and Magnesium Carbonate Irrigation	Cladribine Injection
Clemastine Fumarate Syrup	Clobetasol Propionate Gel	Clonazepam Orally Disintegrating Tablets
Clorazepate Dipotassium Capsules	Clorazepate Dipotassium Extended-Release Tablets	Clotrimazole and Betamethasone Dipropionate Lotion
Colestipol Hydrochloride Tablets	Colfosceril and Tyloxapol Suspension	Compound Undecylenic Acid Cream
Compound Undecylenic Acid Topical Powder	Conjugated Estrogens and Medroxyprogesterone Acetate Tablets	Cromolyn Sodium Nasal Solution
Cyclosporine Modified Capsules	Cyclosporine Modified Oral Solution	Cyclosporine Ointment
Cyclosporine Topical Solution	Cysteamine Bitartrate Capsules	Cytarabine Liposome Injection
Dalfopristin and Quinupristin Injection	Dantrolene Sodium Oral Suspension	Dapiprazole for Ophthalmic Solution
Desirudin for Injection	Desonide Cream	Dexrazoxane for Injection
Dextroamphetamine Sulfate Extended-Release Capsules	Dextromethorphan Polistirex Extended-Release Oral Suspension	Diazepam Injectable Emulsion
Diclofenac Sodium Ophthalmic Solution	Diethylpropion Hydrochloride Extended-Release Tablets	Difenoxin and Atropine Tablets
Difloxacin Hydrochloride Tablets	Dihydroergotamine Mesylate Metered Spray	Diltiazem Malate Extended-Release Tablets
Dinoprostone Vaginal Suppositories	Diphenhydramine Hydrochloride and Acetaminophen Tablets	Divalproex Sodium Delayed-Release Capsules
Dorzolamide and Timolol Ophthalmic Solution	Dorzolamide Ophthalmic Solution	Doxacurium Chloride Injection
Doxepin Hydrochloride Cream	Doxycycline Oral Gel	Econazole Nitrate Cream
Edrophonium Chloride and Atropine Sulfate Injection	Enalapril Maleate and Diltiazem Malate Extended-Release Tablets	Enalapril Maleate and Felodipine Extended-Release Tablets
Enalaprilat Injection <b>(Received)</b>	Entacapone Tablets	Ephedrine Sulfate and Guaifenesin Tablets
Epoprostenol for Injection	Epoprostenol Injection	Esmolol Hydrochloride Injection
Esomeprazole Magnesium Capsules	Estazolam Tablets	Estramustine Phosphate Sodium Capsules
Ethanolamine Oleate Injection	Etidronate Disodium Injection Concentrate	Etomidate Injection
Exemestane Tablets	Famotidine Orally Disintegrating Tablets	Felbamate Oral Suspension
Felbamate Tablets	Fentanyl Lozenges	Fentanyl Transdermal System <b>(Received)</b>
Ferrous Fumarate and Docusate Sodium Extended-Release Capsules	Flavoxate Hydrochloride Tablets	Fluconazole Injection <b>(Received)</b>
Fluconazole Tablets	Flunisolide Inhalation Aerosol	Flunisolide Nasal Spray
Fluocinolone Acetonide Shampoo	Fluorescein Sodium Ophthalmic Solution	Fluorometholone Ointment
Fluticasone Propionate Cream <b>(Received)</b>	Fluticasone Propionate Inhalation Powder	Fluticasone Propionate Ointment <b>(Received)</b>
Fluticasone Propionate Pressurized Inhaler	Foscarnet Sodium Injection	Fosfomycin for Oral Solution
Gabapentin Oral Solution	Gabapentin Tablets <b>(Received)</b>	Gadobenate Dimeglumine Injection
Galantamine Tablets <b>(Received)</b>	Gallium Nitrate Injection	Ganciclovir Capsules
Ganirelix Acetate Injection	Gatifloxacin Injection	Gatifloxacin Tablets
Gentamicin Sulfate Oral Solution	Gentamicin Sulfate Soluble Powder	Glimepiride Tablets <b>(Received)</b>
Glipizide Extended-Release Tablets	Granisetron Injection	Granisetron Tablets
Guaifenesin and Salts Of Dextromethorphan and Pseudoephedrine Oral Solution	Guaifenesin and Pseudoephedrine Hydrochloride Extended-Release Tablets	Guanidine Hydrochloride Tablets
Halobetasol Propionate Cream	Halobetasol Propionate Ointment	Haloperidol Decanoate Injection
Haloperidol Lactate Injection	Haloperidol Lactate Oral Concentrate	Hydralazine Hydrochloride and Hydrochlorothiazide Capsules
Hydrochlorothiazide Capsules	Hydrochlorothiazide Oral Solution Concentrate	Hydrocodone Bitartrate and Acetaminophen Oral Solution
Hydrocodone Bitartrate and Aspirin Tablets	Hydrocodone Bitartrate and Guaifenesin Oral Solution	Hydrocodone Bitartrate and Homatropine Methylbromide Syrup

Noncomplex Actives (Drug Products) (Continued)

Hydrocodone Bitartrate and Homatropine Methylbromide Tablets	Hydrocortisone Acetate Dental Paste	Hydrocortisone Acetate Rectal Foam Aerosol
Hydrocortisone Butyrate Lotion	Hydroflumethiazide and Reserpine Tablets	Hydromorphone Hydrochloride Oral Solution <b>(Received)</b>
Hydroquinone Lotion	Ibandronate Sodium Tablets	Ibuprofen Capsules
Idarubicin Hydrochloride Injection	Imipramine Pamoate Capsules	Imiquimod Topical Cream
Ipratropium Bromide Inhalation Aerosol	Ipratropium Bromide Inhalation Solution	Irinotecan Hydrochloride Injection
Isosulfan Blue Injection	Isradipine Extended-Release Tablets	Itraconazole Injection
Itraconazole Oral Solution	Ketoconazole Cream	Ketoconazole Shampoo
Ketoprofen Capsules <b>(Received)</b>	Ketoprofen Extended-Release Capsules	Ketoprofen Tablets
Ketotifen Fumarate Ophthalmic Solution	Lactic Acid Lotion	Lamivudine Tablets <b>(Received)</b>
Lamotrigine Tablets	Latanoprost Ophthalmic Solution	Leucovorin Calcium for Injection
Levetiracetam Tablets	Levobetaxolol Ophthalmic Suspension	Levocabastine Ophthalmic Suspension
Levofloxacin Solution	Levomethadyl Acetate Hydrochloride Oral Concentrate	Lincomycin Hydrochloride and Spectinomycin Sulfate Soluble Powder
Liothyronine Injection	Lisinopril and Hydrochlorothiazide Tablets <b>(Received)</b>	Lomustine Capsules
Lopinavir and Ritonavir Solution	Lopinavir Capsules	Lopinavir Solution
Loratadine and Pseudoephedrine Sulfate Extended-Release Tablets <b>(Received)</b>	Loratadine Orally Disintegrating Tablets	Losartan Potassium Tablets
Mefloquine Hydrochloride Tablets	Melphalan for Injection	Mesalamine Suppositories
Mesoridazine Besylate Concentrate	Metaraminol Bitartrate Injection	Methacholine Chloride for Inhalation Solution
Methadone Hydrochloride Oral Concentrate	Methocarbamol and Aspirin Tablets	Methoxsalen Softgels
Methyclothiazide and Deserpidine Tablets	Methylphenidate Hydrochloride Chewable Tablets	Metipranolol Ophthalmic Solution
Metronidazole Capsules	Metronidazole Cream	Metronidazole Extended-Release Tablets
Metronidazole Hydrochloride for Injection	Metronidazole Lotion	Miconazole Nitrate Topical Aerosol
Midazolam Injection <b>(Received)</b>	Mifepristone Tablets	Miglitol Tablets
Milrinone Injection	Misoprostol Tablets <b>(Received)</b>	Mivacurium In Dextrose Injection
Mivacurium Injection	Moexipril Hydrochloride and Hydrochlorothiazide Tablets	Moexipril Hydrochloride Tablets
Molindone Hydrochloride Oral Solution	Morphine Sulfate for Injection Concentrate	Morphine Sulfate Oral Solution
Morphine Sulfate Oral Solution Concentrate	Morphine Sulfate Tablets	Mycophenolate Mofetil Capsules
Mycophenolate Mofetil Oral Solution	Mycophenolate Mofetil Tablets	Nalbuphine Hydrochloride Injection
Nalmefene Hydrochloride Injection	Naphazoline Hydrochloride and Pheniramine Maleate Ophthalmic Solution	Naphazoline Hydrochloride and Pheniramine Maleate Ophthalmic Solution
Naproxen Extended-Release Tablets	Nateglinide Tablets	Nedocromil Sodium Inhalation Aerosol
Neomycin Sulfate Oral Powder	Nicardipine Hydrochloride Capsules	Nilutamide Tablets
Nimodipine Capsules	Nisoldipine Extended-Release Tablets	Nitroglycerin Extended-Release Transdermal Film
Nitroglycerin Transdermal System	Nitroglycerin Solution In Acrylic Adhesive	Nizatidine Tablets
Ofloxacin In Dextrose Injection	Ofloxacin Injection	Ofloxacin Tablets <b>(Received)</b>
Olopatadine Ophthalmic Solution <b>(Received)</b>	Olsalazine Sodium Capsules	Ondansetron Tablets
Orbifloxacin Tablets <b>(Received)</b>	Orlistat Capsules <b>(Received)</b>	Orphenadrine Citrate Extended-Release Tablets
Orphenadrine Citrate, Aspirin, and Caffeine Tablets	Oxcarbazepine Suspension	Oxcarbazepine Tablets
Oxiconazole Cream	Pantoprazole Sodium for Injection	Pantoprazole Sodium Tablets
Paroxetine Hydrochloride Extended-Release Tablets	Paroxetine Oral Suspension	Pemirolast Potassium Ophthalmic Solution
Pemoline Tablets	Penicillin G Potassium Tablets for Oral Solution	Pentamidine Isethionate for Inhalation

## Noncomplex Actives (Drug Products) (Continued)

Pentamidine Isethionate Injection <i>(Received)</i>	Pentazocine Hydrochloride and Acetaminophen Tablets	Phendimetrazine Tartrate Extended-Release Capsules
Phenobarbital Capsules	Phentermine Resin Complex Capsules	Phenylephrine Hydrochloride and Chlorpheniramine Maleate Extended-Release Capsules
Phenylephrine Hydrochloride, Chlorpheniramine Maleate, and Acetaminophen Extended-Release Tablets	Pilocarpine Hydrochloride Ophthalmic Gel	Pilocarpine Hydrochloride Ophthalmic Ointment
Pilocarpine Hydrochloride Tablets	Piperonyl Butoxide and Pyrethrins Aerosol Foam	Pirbuterol Acetate Inhalation Aerosol
Poractant Alpha Suspension	Porfimer Sodium for Injection	Povacrylate Solution
Povacrylate–Iodine Topical Solution	Povidone–Iodine Gauze	Povidone–Iodine Swabsticks
Povidone–Iodine Topical Aerosol Foam	Povidone–Iodine Vaginal Suppositories	Pramipexole Dihydrochloride Tablets
Prednisolone Sodium Phosphate Oral Solution	Prochlorperazine Maleate Extended-Release Capsules	Progesterone Capsules
Promethazine and Phenylephrine Hydrochlorides and Codeine Phosphate Syrup	Promethazine and Phenylephrine Hydrochlorides Syrup	Promethazine Hydrochloride and Codeine Phosphate Oral Solution
Promethazine Hydrochloride and Dextromethorphan Hydrobromide Syrup	Propafenone Hydrochloride Tablets	Pseudoephedrine Hydrochloride and Brompheniramine Maleate Extended-Release Tablets
Pseudoephedrine Hydrochloride and Naproxen Sodium Extended-Release Tablets	Pseudoephedrine Hydrochloride, Chlorpheniramine Maleate, and Codeine Phosphate Oral Solution	Pseudoephedrine Hydrochloride, Guaifenesin, and Codeine Phosphate Oral Solution
Pseudoephedrine Sulfate and Dexbrompheniramine Maleate Extended-Release Tablets	Pseudoephedrine Sulfate and Dexbrompheniramine Maleate Oral Solution	Pseudoephedrine Sulfate, Dexbrompheniramine Maleate, and Acetaminophen Extended-Release Tablets
Pyrilamine Maleate Injection		
Quinidine Sulfate Injection	Ramipril Capsules	Ranitidine Capsules
Rauwolfia Serpentina and Endroflumethiazide Tablets	Reserpine and Polythiazide Tablets	Rimantadine Hydrochloride Oral Solution
Risperidone Oral Solution	Risperidone Orally Disintegrating Tablets	Rivastigmine Tartrate Capsules
Rivastigmine Tartrate Oral Solution <i>(Received)</i>	Rocuronium Bromide Injection	Ropinirole Hydrochloride Tablets
Rose Bengal Ophthalmic Solution	Rosiglitazone Maleate Tablets	Salicylic Acid and Sulfur Cleansing Lotion
Salicylic Acid and Sulfur Lotion	Salicylic Acid and Sulfur Shampoo	Salicylic Acid Cream
Salicylic Acid Ointment	Salmeterol Inhalation Aerosol	Salmeterol Xinafoate Inhalation Powder
Scopolamine Transdermal System	Selegiline Hydrochloride Capsules	Sertraline Hydrochloride Oral Solution
Sibutramine Hydrochloride Capsules	Sodium Bicarbonate and Sodium Citrate for Oral Solution	Sodium Bicarbonate, Sodium Citrate, and Sodium Tartrate for Oral Suspension
Sodium Iodide Injection	Sodium Phenylbutyrate Oral Powder	Sodium Phenylbutyrate Tablets
Sodium Phosphates for Oral Suspension	Sodium Phosphates Tablets	Sodium Salicylate and Sulfur Shampoo
Sterile Talc Aerosol	Streptozocin for Injection	Sucralfate Oral Suspension
Sulconazole Nitrate Cream	Sulfacetamide Sodium and Fluorometholone Ophthalmic Suspension	Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution
Sulfacytine Tablets	Sulfasalazine Oral Suspension	Sulisobenzone Lotion
Sumatriptan Injection	Sumatriptan Tablets	Tacrolimus Capsules
Tacrolimus Injection	Tacrolimus Ointment	Tamsulosin Hydrochloride Capsules <i>(Received)</i>
Technetium Tc 99M Teboroxime Injection	Tenofovir Disoproxil Fumarate Tablets	Terbinafine Hydrochloride Cream
Terbinafine Tablets <i>(Received)</i>	Terbinafine Topical Solution	Terconazole Vaginal Cream
Terconazole Vaginal Suppositories	Testosterone Transdermal System	Tetracycline Hydrochloride Periodontal Fiber
Theophylline Extended-Release Tablets	Tioconazole Vaginal Ointment	Tiopronin Tablets
Tolnaftate Topical Aerosol Solution	Topiramate Capsules <i>(Received)</i>	Topiramate Tablets <i>(Received)</i>
Torsemide Injection	Torsemide Tablets <i>(Received)</i>	Trandolapril and Verapamil Hydrochloride Extended-Release Tablets
Trandolapril Tablets	Tranexamic Acid Injection	Tranlycypromine Sulfate Tablets
Tretinoin Capsules	Tretinoin Microsphere Gel	Triamcinolone Acetonide Nasal Suspension
Trifluridine Ophthalmic Solution	Trimetrexate for Injection	Trimipramine Maleate Capsules
Tripolidine and Pseudoephedrine Hydrochlorides and Codeine Phosphate Syrup	Trolamine Salicylate Cream	Trolamine Salicylate Gel
Trolamine Salicylate Topical Emulsion	Trovaflaxacin Injection	Trovaflaxacin Mesylate for Injection

Noncomplex Actives (Drug Products) (Continued)

Undecylenic Acid Topical Foam Aerosol	Unoprostone Isopropyl Ophthalmic Solution	Urea Cream
Vecuronium Bromide for Injection	Venlafaxine Extended-Release Capsules <i>(Received)</i>	Venlafaxine Tablets
Verapamil Hydrochloride Capsules	Verapamil Hydrochloride Extended-Release Capsules	Voriconazole Injection
Voriconazole Oral Suspension	Voriconazole Tablets	Yttrium Y-90 Chloride Solution
Yttrium Y-90 Glass Microspheres	Yttrium Y-90 Microspheres Injection	Zidovudine and Lamivudine Tablets <i>(Received)</i>
Zinc Acetate Capsules	Zinc Tridosium Pentetate Injection	Ziprasidone Hydrochloride Capsules
Zoledronic Acid for Injection		

Excipients

Acetone Sodium Bisulfite	Acetylated Monoglycerides	Aconitic Acid (Achilleic Acid)
Acrylic Acid–Octyl Acrylate Copolymer	Albumin Colloidal	Aliphatic Polyesters
Allantoin–Sodium Pyrrolidone Carboxylate	Aluminum Ammonium Sulfate	Aluminum Lactate
Aluminum Oxide	Aluminum Potassium Sulfate	Aluminum Silicate
Aluminum Sodium Sulfate	Aluminum Stearate	Ammonium Bicarbonate
Ammonium Calcium Alginate	Ammonium Phosphate	Batylalcohol Monostearate
Beeswax, Synthetic	Benzododecinium Bromide	Benzyl Chloride
Benzyl Nicotinate	Beta Naphthol	Brominated Vegetable Oil
Butadiene–Styrene Rubber	Butylated Hydromethylphenol	Butylene Glycol
Butylphthalyl Butylglycolate	Calcium Acid Pyrophosphate	Calcium Alginate
Calcium Alginate and Ammonium Alginate	Calcium Bromide	Calcium Chloride Solution
Calcium Glycerophosphate <i>(Received)</i>	Calcium Phosphate Monobasic	Calcium Propionate
Calcium Pyrophosphate	Calcium Sorbate	Calcium Stearoyl Lactylate
Caldiamide Sodium	Calteridol Calcium	Canola Oil
Capric Acid	Caprylic/Capric Diglyceryl Succinate	Carbon
Carboxymethyl Starch	Carboxymethylamylopectin Sodium	Carboxymethylcellulose Potassium
Cetostearyl Isononanoate	Chlorodifluoroethane	Cholic Acid
Cinnamaldehyde	Cocamide Diethanolamine	Cocamide Oxide
Cocoyl Caprylocaprate	Crystal Gum	Cutina
Cystine	Dammar Gum	Decanoic Acid
Decyl Oleate	Dehydroacetic Acid	Desoxycholic Acid
Dextrin Palmitate	Dextrins Modified	Diacetyl Tartaric Acid Esters Of Mono- and Diglycerides
Dicetyl Phosphate	Dichlorodifluoromethane	Diethyl Sebacate
Difluoroethane	Diglycol Stearate	Diisobutyl Adipate
Diisopropyl Adipate	Diisopropylbenzothiazyl-2-Sulfenamide	Dilauryl Thiodipropionate
Dimethyl Dicarboxylate	Dimyristoyl Lecithin	Dimyristoyl Phosphatidylglycerol
Dipropylene Glycol	Disodium Edisylate	Disodium Guanylate
Disodium Inosinate	Disodium Monooleamide Sulfasuccinate	D-Mannose
Docusate Sodium/Sodium Benzoate	Erythorbic Acid	Erythrosine
Ethoxylated Mono- and Diglycerides	Ethoxyquin	Ethyl Hexanediol
Ethyl Linoleate	Ethyl Maltol	Ethylene Dichloride
Ethylurea	Ferric Ammonium Citrate	Ferric Citrate
Ferric Oxide, Brown	Ferric Phosphate	Ferric Pyrophosphate
Ferrous Citrate	Ferrous Glycinate	Ferrous Lactate
Fluorochlorohydrocarbons	Formic Acid	Furcelleran
Gamma-Cyclodextrin <i>(Received)</i>	Gentistic Acid	Geraniol
Glutamic Acid Hydrochloride	Gluten	Glycerol Ester Of Gum Rosin (Ester Gum)
Glyceryl Laurate	Glyceryl Palmitate	Glyceryl Ricinoleate
Glyceryl Tristearate	Glycine Hydrochloride	Glycofurol
Glycol Stearate	Heptafluoropropane	Heptylparaben
Hexadecyl Isostearate	Hexane	Hexanetriol(-1,2,6-)
Hydrocarbon Gel	Hydrogenated Starch Hydrolysate	Hydroxyethylmethylcellulose
Hydroxylated Lecithin	Hydroxypropyl Beta Cyclodextrin	Indigotine

## Excipients (Continued)

Inositol	Iron Carbonyl	Iron Subcarbonate
Isobutylated-Isoprene Copolymer	Isooctylacrylate	Isopropyl Isostearate
Isopropyl Stearate	Isostearic Acid	Isostearyl Alcohol
Lactobionic Acid	Lactose Ferrin, Bovine	Lactylated Fatty Acid Esters Of Glycerol and Propylene Glycol
Lactylic Esters Of Fatty Acids	Lanolin (Wool Fat), Hydrogenated	Lanolin Alcohols, Acetylated
Lanolin Hydrous	L-Ascorbyl Stearate	Lauramine Oxide
Lauric Myristic Diethanolamide	Lauric Acid	Lauric Diethanolamide
Lavender Oil	L-Cysteine Monohydrochloride	Lecithin, Hydroxylated
L-Glutamic Acid	Linoleic Acid	L-Leucine
Macrogol Sorbitan Tristearate	Macrogolglycerol Cocoates	Macrogolglycerol Triisostearate
Magnesium Aluminum Silicate Hydrate	Magnesium Aspartame Dihydrate	Magnesium Aspartate
Magnesium Phosphate Tribasic	Magnesium Phosphate, Diabasic, Trihydrate	Magnesium Tartrate
Malt Syrup	Maltitol Syrup	Maltol Isobutyrate
Manganese Chloride	Manganese Citrate	Manganese Glycerophosphate
Manganese Hypophosphite	Medical Antifoam Emulsion C	Medronate Disodium
Medronic Acid	Methyl Chloride	Methylchloroisothiazolinone
Methylisothiazolinone	Microcrystalline Cellulose, Silicified <b>(Received)</b>	Mineral Spirits
Monoisostearyl Glyceryl Ester	Monopotassium Glutamate Monohydrate	Monosodium Citrate
Mullein Leaf	Myristyl Gamma-Picolinium Chloride	Myristyl Lactate
<i>N,N</i> -Bis(2-hydroxyethyl)stearamide	<i>N</i> -Acetyl-L-Methionine	Naphtha
<i>N</i> -Methylpyrrolidone <b>(Received)</b>	Non-Pareil Seeds	Nutmeg Oil
Octanoic Acid	Oxystearin	Palm Oil
Pentasodium Triphosphate	Pentetate Calcium Trisodium	Pentetate Pentasodium
Phenprobamate	Phenylmercuric Acetate	Phenylmercuric Nitrate
Pine Oil	Polacrilin	Polydextrose Solution
Polyglycerol Esters of Fatty Acids	Polyglycerol Polyricinoleic Acid	Polyoxyethylene Castor Oil (USP has 35)
Polyoxyl Stearate (USP has 40)		
Polypropylene Oleate	Polypropylene Stearyl Ether	Polysorbate 65
Polyvinylacetal	Polyvinylacetal Diethylanoacetate	Polyvinylpyrrolidone
Polyvinylpyrrolidone Ethylcellulose	Potassium Acid Tartrate	Potassium Bromate
Potassium Carbonate Solution	Potassium Dichloroisocyanurate	Potassium Gibberellate
Potassium Glycerophosphate	Potassium Iodate	Potassium Nitrite
Potassium Phosphate	Potassium Phosphate Tribasic	Potassium Polymetaphosphate
Potassium Pyrophosphate	Potassium Stearate	Potassium Sulfate
Potassium Sulfite	Potassium Tripolyphosphate	Propyl Propionate
Propylene Glycol Diacetate	Propylene Glycol Mono- and Diesters	Purified Poxyl 35 Castor Oil <b>(Received)</b>
Rapeseed Oil, Hydrogenated <b>(Received)</b>	Rapeseed Oil, Superglycerinated <b>(Received)</b>	Rice Bran Wax
Rosin	Silicone	Sodium Acid Pyrophosphate
Sodium Aluminosilicate	Sodium Aluminum Phosphate Acidic	Sodium Aluminum Phosphate Basic
Sodium Aspartate	Sodium Bisulfate	Sodium Bisulfite
Sodium Carbonate Hydrate	Sodium Carboxymethyl Betaglucon	Sodium Caseinate
Sodium Chlorate	Sodium Citrate, Dibasic	Sodium Citrate, Monobasic
Sodium Dehydroacetate	Sodium Diacetate	Sodium Erythorbate
Sodium Ferric Pyrophosphate	Sodium Ferrocyanide	Sodium Hypophosphite
Sodium Laureth Sulfate	Sodium Lauroyl Sarcosinate	Sodium Lauryl Sulfoacetate
Sodium Magnesium Aluminosilicate	Sodium Magnesium Silicate	Sodium Malate
Sodium Metaphosphate, Insoluble	Sodium Metasilicate	Sodium Methylate
Sodium Polyphosphates Glassy	Sodium Potassium Tripolyphosphate	Sodium Pyrophosphate
Sodium Pyrrolidone Carboxylate	Sodium Sesquicarbonate	Sodium Sesquinoate
Sodium Stearoyl Lactylate	Sodium Thiomalate	Sodium Trimetaphosphate
Sodium Trioleate	Sodium Tripolyphosphate	Soy Polysaccharides
Stannous Chloride	Stannous Tartrate	Starch, Pregelatinized Corn
Starch, Pregelatinized Tapioca	Stearalkonium Chloride	Stearyl Citrate
Stearyl Monoglyceridyl Citrate	Succinylated Monoglycerides	Sucrose Acetate Isobutyrate

Excipients (Continued)

Sucrose Fatty Acid Esters	Sucrose Stearate	Sugar Fruit Fine
Sulfobutyl Ether Beta Cyclodextran	Tallow	Tallow Glycerides
Tallow Oil	Tetrafluoroethane	Thioglycerol
Thyme Oil	Tribehenin	Triceteareth-4 Phosphate
Trichloroethylene	Trimyristin	Trisodium Citrate
Trolamine Lauryl Sulfate	Vegetable Oil	Wheat Flour
Wheat Germ Oil	Wheat Gluten <b>(Received)</b>	Whey

## Instructions to Authors

Contributions in the form of original research reports, evaluations of new and existing compendial methods, and other commentaries and articles relevant to drug standards or to *USP–NF* revision will be considered for publication in the *Pharmacopeial Forum* under the section *Stimuli to the Revision Process*. Manuscripts are received with the explicit understanding that they have not been published previously and that they are not simultaneously under consideration by any other publication.

All manuscripts are subject to review by USP headquarters staff, Committee members, or qualified outside referees, and if accepted for publication will be subject to editing by USP staff. Accepted manuscripts become the property of the USP Convention (USPC) and may not be published elsewhere without written permission from the USPC. Authors are also responsible for obtaining permission for reprinting any illustrations that have been published elsewhere.

**Abstract**—Include an abstract of not more than 250 words stating the purpose and the results or conclusions of the article.

**References**—Consult a current copy of the *Pharmacopeial Forum* and the *ACS Style Guide* for assistance with reference style.

**Copyright**—Copyright transfer documents will be sent to authors after manuscripts have been accepted for publication.

**Contact Person**—When submitting a manuscript, designate one author of the article as correspondent and include that author's full address, telephone number, fax number, and e-mail address.

**Submission Instructions**—Manuscripts must be submitted both as an electronic file and as a printed copy of the electronic file. Submit the text in Microsoft® Word or another current word-processing application. The preferred format for graphics submitted electronically is tagged image file format (TIFF). Graphics that cannot be submitted electronically must be camera-ready, of easily reproducible quality and size, and clearly labeled. Photocopies are not acceptable. Manuscripts submitted for publication should be addressed to:

Pharmacopeial Forum  
Executive Secretariat, USP  
12601 Twinbrook Pkwy.  
Rockville, MD 20852